脂蛋白(a)升高在冠状动脉旁路移植术中的新意义
该综述检索PubMed/MEDLINE至2024年3月,评估脂蛋白(a)与冠心病及CABG结局的关系。文献支持脂蛋白(a)是冠心病的因果独立危险因素,其升高与移植物闭塞和主要不良心血管事件风险增加相关,作者倡导所有CABG患者常规检测脂蛋白(a)。
要点
- 脂蛋白(a)是冠心病的因果独立危险因素。
- 脂蛋白(a)升高与CABG后移植物闭塞和主要不良心血管事件风险增加相关。
- 倡导所有CABG患者常规检测脂蛋白(a),降脂蛋白(a)新药前景可期。
核心结论
- 脂蛋白(a)水平可能有助于接受外科血运重建的冠心病患者风险分层并指导围术期管理。
- 倡导所有接受CABG的患者常规检测脂蛋白(a)。
- 新兴降脂蛋白(a)药物在心脏外科亚组中的专门分析对评估其改善CABG结局的作用很重要。
研究设计与样本
- 综述检索PubMed/MEDLINE数据库至2024年3月,纳入评估或描述脂蛋白(a)与CABG手术或冠心病结局关系的文献。
主要发现
- 现有文献支持脂蛋白(a)是冠心病发病的因果独立危险因素。
- 脂蛋白(a)水平升高与CABG后不良结局风险增加相关,包括移植物闭塞发生率和主要不良心血管事件。
- 影响脂蛋白(a)水平的遗传变异在疾病进展和手术结局中起作用。
- 多种旨在降低脂蛋白(a)水平的疗法目前处于III期临床试验,显示出改善CABG后预后的前景。
临床怎么用
- 对接受CABG的患者常规测量脂蛋白(a)以辅助风险定义和围术期管理决策。
- 关注处于III期临床试验的降脂蛋白(a)药物,但需等待心脏外科亚组分析评估其改善CABG结局的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coronary artery bypass grafting (CABG) remains a cornerstone in the management of coronary artery disease (CAD). In nonurgent surgical revascularization cases, preoperative optimization of modifiable risk factors can improve outcomes. There is increasing interest in the relationship between lipoprotein(a) levels and the risk for ischemic cardiovascular disease, particularly how CABG outcomes are in turn affected. This review highlights the role of lipoprotein(a) in the pathogenesis of CAD and CABG outcomes and discusses future directions for its optimal management in the perioperative period. METHODS: The PubMed/MEDLINE database was reviewed until March 2024 to capture publications that evaluated and/or described the relationship between lipoprotein(a) and CABG surgery or CAD outcomes. RESULTS: The available literature supports lipoprotein(a) as a causal and independent risk factor for the pathogenesis of CAD. Elevated lipoprotein(a) levels are associated with an increased risk of adverse post-CABG outcomes, including graft occlusion incidence and major adverse cardiovascular events. Genetic variations influencing lipoprotein(a) levels play a role in disease progression and surgical outcomes. Several therapies aimed at reducing lipoprotein(a) levels, currently in phase III clinical trials, show promise for improving the prognosis after CABG. CONCLUSIONS: Among individuals undergoing surgical revascularization for CAD, lipoprotein(a) levels may help define risk and inform best practices for perioperative management. We advocate for the routine measurement of lipoprotein(a) in all patients undergoing CABG. Emerging lipoprotein(a)-lowering agents show promise for secondary prevention of cardiac events, although dedicated analyses in cardiac surgical subcohorts will be important to evaluate their role in improving CABG outcomes.
引用
- Patel SK, Badross MS, Dhingra NK, et al. Emerging Implications of Elevated Lipoprotein(a) Levels in Coronary Artery Bypass Graft Surgery. Ann Thorac Surg. 2025. PMID: 39889843. doi:10.1016/j.athoracsur.2025.01.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。